4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Change in Accured Expenses data on file, last reported at -$4.1 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.1 million, down 78.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (down 3.94% YoY), and the FY2025 annual result was $8.2 million, up 24.95% from the prior year.
• Change in Accured Expenses declined to -$4.1 million in Q1 2026 per FDMT's latest filing, from $2.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $8.1 million in Q3 2024 and troughed at -$4.1 million in Q1 2026.
• A 5-year average of $965235.3 and a median of $1.2 million in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 240.75% in 2022, then slumped 218.48% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $1.8 million in 2022, then advanced by 9.54% to $2.0 million in 2023, then tumbled by 218.48% to -$2.4 million in 2024, then surged by 200.25% to $2.4 million in 2025, then sank by 273.82% to -$4.1 million in 2026.
• Business Quant data shows FDMT's Change in Accured Expenses at -$4.1 million in Q1 2026, $2.4 million in Q4 2025, and $5.0 million in Q3 2025.